Breast Cancer Therapy
Desferal inhibits breast tumors and does not interfere with doxorubicin
Published in Cancer Weekly, December 6th, 2005
According to a study from the United States, "Desferal is a clinically approved iron chelator used to treat iron overload. Doxorubicin is an anthracycline cancer chemotherapy drug used in the treatment of breast cancer. It can undergo redox cycling in the presence of iron to produce reactive oxygen species. The oxidant-generating activity of doxorubicin is thought to be responsible for the cardiotoxic side effects of the drug, but it is unclear whether it is also required for its anti-tumor activity."
"To test whether an iron-chelating...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-12-06)
More Articles from Cancer Weekly
- Adverse Drug Reaction
Adverse drug reactions might occur during lymphatic mapping and sentinel lymph node biopsy - Apoptosis
Inhibition of JAK3/STAT3 signaling induced apoptosis of colon carcinoma cells - Carcinogenesis
Aluminium, a component of antiperspirants, implicated in breast cancer - Soft Tissue Sarcomas
Surgery recommended for treating adult head and neck soft tissue sarcomas - Surgery
Improved long-term survival linked to resection at high-volume cancer centers - Acute Myeloid Leukemia
Clofarabine's duration of response improves outcome for elderly AML patients - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
